학술논문
Phase I study of mirvetuximab soravtansine (MIRV) and rucaparib for recurrent endometrial, platinum-resistant ovarian, fallopian tube or primary peritoneal cancer
Document Type
Abstract
Author
Source
In Gynecologic Oncology August 2021 162 Supplement 1:S68-S69
Subject
Language
ISSN
0090-8258